Emerging evidence has demonstrated that microRNAs (miRNAs) are intensively engaged in lipid and lipoprotein metabolism by regulating genes involved in control of intracellular lipid synthesis, mitochondrial fatty acid oxidation, and lipoprotein assembly. Mitochondrial dysfunction induced by altered miRNA expression has been proposed to be a contributing factor in the onset of metabolic diseases, while at the same time, aberrant expression of certain miRNAs is associated with the induction of endoplasmic reticulum (ER) stress induced by nutrient-surplus. These studies position miRNAs as a link between oxidative stress and ER stress, two cellular stress pathways that are deregulated in metabolic disease and are associated with very-low-density lipoprotein (VLDL) overproduction. Dyslipoproteinemia frequently accompanied with metabolic syndrome is initiated largely by the overproduction of VLDL and altered biogenesis of high-density lipoprotein (HDL). In this review, we highlight recent findings on the regulatory impact of miRNAs on the metabolic homeostasis of mitochondria and ER as well as their contribution to the aberrant biogenesis of both VLDL and HDL in the context of metabolic disorders, in an attempt to gain further insights into the molecular mechanisms of dyslipidemia in the metabolic syndrome. microRNAs; fatty acid metabolism; ER stress; inflammation; lipoprotein metabolism IN 2011, THE INTERNATIONAL DIABETES FEDERATION estimated that 366 million people suffered from diabetes worldwide (97), with as much as 95% of cases attributed to type 2 diabetes (44). Several pathological conditions usually underlie type 2 diabetes, which together are known as the metabolic syndrome and include obesity, hypertension, glucose intolerance, insulin resistance, and dyslipidemia (62). Dyslipidemia is characterized by increased plasma triglyceride (TG) and free fatty acids (FAs), attributed to increased production of very-low-density lipoprotein (VLDL), as well as increased small dense lowdensity lipoprotein (LDL) and decreased high-density lipoprotein (HDL) (4). This lipid profile gives rise to an increased risk of cardiovascular disease (45), which is currently the leading cause of death in North America (68).
Metabolic Syndrome and Lipoprotein DeregulationThe link between insulin resistance and increased VLDL secretion has been thought to be derived from increased delivery of FAs to the liver secondarily to increased lipolysis within adipose tissue, as well as increased hepatic lipogenesis, increased levels and activity of microsomal triglyceride transfer protein (MTP), and loss of insulin's ability to direct apolipoprotein B (apoB) toward degradation (2, 3, 67). Assembly and secretion of VLDL is a complicated process that takes place in the hepatic endoplasmic reticulum (ER) and is regulated by multiple factors. Co-and posttranslational lipidation of apoB, a key structural protein of VLDL, mediated by MTP is a critical step in VLDL assembly (17,38,48). In fact, mutations in the MTP gene result in a condition known as a...